N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Status:
Completed
Trial end date:
2020-11-06
Target enrollment:
Participant gender:
Summary
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an
neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in
participants with NMO/NMOSD.